PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
200.87
Positive P/E while Drug Manufacturers - Specialty & Generic median is negative at -0.51. Peter Lynch would investigate competitive advantages in a distressed Drug Manufacturers - Specialty & Generic.
30.02
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.63. Jim Chanos would check for potential multiple compression risks.
1.05
P/B 50-90% of Drug Manufacturers - Specialty & Generic median of 1.35. Mohnish Pabrai would examine if this discount presents opportunity.
-188.87
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -1.86. Seth Klarman would investigate cash flow improvement potential.
-272.05
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is 0.00. Seth Klarman would investigate operational improvement potential.
1.05
Fair value ratio 50-90% of Drug Manufacturers - Specialty & Generic median of 1.35. Mohnish Pabrai would examine if this gap presents opportunity.
0.12%
Positive earnings while Drug Manufacturers - Specialty & Generic median shows losses. Peter Lynch would examine earnings quality advantage.
-0.53%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.01%. Seth Klarman would investigate cash flow improvement potential.